BACKGROUND: The drip-and-ship method of treating stroke patients may increase the use of tissue plasminogen activator (t-PA) in community hospitals. OBJECTIVE: The safety and early outcomes of patients treated with t-PA for acute ischemic stroke (AIS) by the drip-and-ship method were compared to patients directly treated at a stroke center. METHODS: The charts of all patients who were treated with intravenous (i.v.) t-PA at outside hospitals under the remote guidance of our stroke team and were then transferred to our facility were reviewed. Baseline NIHSS (National Institutes of Health Stroke Scale) scores, onset-to-treatment (OTT), and arrival-to-treatment (ATT) times were abstracted. The rates of in-hospital mortality, symptomatic hemorrhage (sICH), early excellent outcome (modified Rankin Scale [mRS] ≤ 1), and early good outcome (discharge home or to inpatient rehabilitation) were determined. RESULTS: One hundred sixteen patients met inclusion criteria. Eighty-four (72.4%) were treated within 3 h of symptom onset. The median estimated NIHSS score was 9.5 (range 3-27). The median OTT time was 150 min, and the median ATT was 85 min. These patients had an in-hospital mortality rate of 10.7% and sICH rate of 6%. Thirty percent of patients had an early excellent outcome and 75% were discharged to home or inpatient rehabilitation. When these outcome rates were compared with those observed in patients treated directly at our stroke center, there were no statistical differences. CONCLUSIONS: In this small retrospective study, drip-and-ship management of delivering i.v. t-PA for AIS patients did not seem to compromise safety. However, a large prospective study comparing drip-and-ship management to routine care is needed to validate the safety of this approach to treatment.
BACKGROUND: The drip-and-ship method of treating strokepatients may increase the use of tissue plasminogen activator (t-PA) in community hospitals. OBJECTIVE: The safety and early outcomes of patients treated with t-PA for acute ischemic stroke (AIS) by the drip-and-ship method were compared to patients directly treated at a stroke center. METHODS: The charts of all patients who were treated with intravenous (i.v.) t-PA at outside hospitals under the remote guidance of our stroke team and were then transferred to our facility were reviewed. Baseline NIHSS (National Institutes of Health Stroke Scale) scores, onset-to-treatment (OTT), and arrival-to-treatment (ATT) times were abstracted. The rates of in-hospital mortality, symptomatic hemorrhage (sICH), early excellent outcome (modified Rankin Scale [mRS] ≤ 1), and early good outcome (discharge home or to inpatient rehabilitation) were determined. RESULTS: One hundred sixteen patients met inclusion criteria. Eighty-four (72.4%) were treated within 3 h of symptom onset. The median estimated NIHSS score was 9.5 (range 3-27). The median OTT time was 150 min, and the median ATT was 85 min. These patients had an in-hospital mortality rate of 10.7% and sICH rate of 6%. Thirty percent of patients had an early excellent outcome and 75% were discharged to home or inpatient rehabilitation. When these outcome rates were compared with those observed in patients treated directly at our stroke center, there were no statistical differences. CONCLUSIONS: In this small retrospective study, drip-and-ship management of delivering i.v. t-PA for AISpatients did not seem to compromise safety. However, a large prospective study comparing drip-and-ship management to routine care is needed to validate the safety of this approach to treatment.
Authors: I L Katzan; A J Furlan; L E Lloyd; J I Frank; D L Harper; J A Hinchey; J P Hammel; A Qu; C A Sila Journal: JAMA Date: 2000-03-01 Impact factor: 56.272
Authors: S E Kasner; J A Chalela; J M Luciano; B L Cucchiara; E C Raps; M L McGarvey; M B Conroy; A R Localio Journal: Stroke Date: 1999-08 Impact factor: 7.914
Authors: Joe E Acker; Arthur M Pancioli; Todd J Crocco; Marc K Eckstein; Edward C Jauch; Hollynn Larrabee; Neil M Meltzer; William C Mergendahl; John W Munn; Susanne M Prentiss; Charles Sand; Jeffrey L Saver; Brian Eigel; Brian R Gilpin; Mark Schoeberl; Penelope Solis; JoAnne R Bailey; Katie B Horton; Steven K Stranne Journal: Stroke Date: 2007-09-27 Impact factor: 7.914
Authors: K O Lövblad; H J Laubach; A E Baird; F Curtin; G Schlaug; R R Edelman; S Warach Journal: AJNR Am J Neuroradiol Date: 1998 Jun-Jul Impact factor: 3.825
Authors: L B Morgenstern; L D Lisabeth; A C Mecozzi; M A Smith; P J Longwell; D A McFarling; J M H Risser Journal: Neurology Date: 2004-03-23 Impact factor: 9.910
Authors: Muhammad A Pervez; Gisele Silva; Shihab Masrur; Rebecca A Betensky; Karen L Furie; Renzo Hidalgo; Fabricio Lima; Eric S Rosenthal; Natalia Rost; Anand Viswanathan; Lee H Schwamm Journal: Stroke Date: 2009-11-12 Impact factor: 7.914
Authors: Michael J Lyerly; Karen C Albright; Amelia K Boehme; Reza Bavarsad Shahripour; John P Donnelly; James T Houston; Pawan V Rawal; Niren Kapoor; Muhammad Alvi; April Sisson; Anne W Alexandrov; Andrei V Alexandrov Journal: South Med J Date: 2015-07 Impact factor: 0.954
Authors: Ganesh Asaithambi; Ameer E Hassan; Saqib A Chaudhry; Gustavo J Rodriguez; M Fareed K Suri; Robert A Taylor; Mustapha A Ezzeddine; Adnan I Qureshi Journal: J Vasc Interv Neurol Date: 2011-07
Authors: Maarten M H Lahr; Gert-Jan Luijckx; Patrick C A J Vroomen; Durk-Jouke van der Zee; Erik Buskens Journal: J Neurol Date: 2012-08-23 Impact factor: 4.849
Authors: Adnan I Qureshi; Saqib A Chaudhry; Gustavo J Rodriguez; M Fareed K Suri; Kamakshi Lakshminarayan; Mustapha A Ezzeddine Journal: Cerebrovasc Dis Extra Date: 2012